LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Bayhill focused on the translation of research into therapeutics for the treatment of autoimmune diseases. The company pursued DNA-antigen vaccines and oligonucleotides that were specifically designed to promote immune intolerance. The company was dissolved in 2012.
Bayhill Therapeutics
San Mateo, CA
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.